Sightline Wealth Advisors LLC Trims Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Sightline Wealth Advisors LLC decreased its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 5.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 61,937 shares of the company’s stock after selling 3,307 shares during the period. Sightline Wealth Advisors LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $601,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Atria Investments Inc bought a new stake in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at approximately $122,000. Centaurus Financial Inc. purchased a new position in Global X Genomics & Biotechnology ETF during the 2nd quarter worth $146,000. Rockefeller Capital Management L.P. bought a new position in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter worth $205,000. James J. Burns & Company LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 6.0% during the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after buying an additional 1,038 shares during the period. Finally, Sanctuary Advisors LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF in the second quarter valued at about $590,000. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Stock Down 1.0 %

NASDAQ:GNOM traded down $0.10 during mid-day trading on Monday, reaching $9.88. The company’s stock had a trading volume of 59,209 shares, compared to its average volume of 64,516. Global X Genomics & Biotechnology ETF has a 1 year low of $9.52 and a 1 year high of $12.53. The stock has a fifty day moving average of $10.28 and a 200-day moving average of $10.78. The firm has a market capitalization of $68.86 million, a PE ratio of -4.22 and a beta of 1.03.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.